SCHEMBL7142759

SCHEMBL7142759

O=C(CCC1CC(S)CN1S(=O)(=O)c1ccc2ccccc2c1)NCCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
ECE1 P42892 5/20 0.45
MME P08473 2/20 0.45
ACE P12821 2/20 0.45
BDKRB1 P46663 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
MMP1 P03956 1/20 0.41
MMP3 P08254 1/20 0.41
MMP7 P09237 1/20 0.41
MMP9 P14780 1/20 0.41
POLB P06746 2/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
CCR4 P51679 3/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137948 1.00 ALDH1A1 (0.47) ALDH1A1GAAECE1MMEACE
SCHEMBL7138527 0.91 ECE1 (0.47) ALDH1A1ECE1MMEACEBDKRB1
SCHEMBL7145542 0.91 ECE1 (0.47) ALDH1A1ECE1MMEACEBDKRB1
SCHEMBL7147193 0.85 ECE1 (0.48) ALDH1A1GAAECE1MMEACE
SCHEMBL7136953 0.85 ECE1 (0.48) ALDH1A1GAAECE1MMEACE
SCHEMBL7146642 0.83 MME (0.59) ALDH1A1GAAECE1MMEACE
SCHEMBL7144246 0.83 ECE1 (0.48) ECE1MMEACEBDKRB1LMNA
SCHEMBL7135957 0.83 ECE1 (0.48) ECE1MMEACEBDKRB1LMNA
SCHEMBL7147785 0.83 ECE1 (0.45) ALDH1A1ECE1MMEACELMNA
SCHEMBL5409534 0.83 ECE1 (0.45) ALDH1A1ECE1MMEACELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885GAA 130/4885ECE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.